Neurotech International Limited

Equities

NTI

AU000000NTI9

Advanced Medical Equipment & Technology

Market Closed - Australian S.E. Other stock markets 02:10:52 2024-04-24 am EDT			5-day change	1st Jan Change
0.09 ^AUD	-2.17%		-10.00%	+30.43%

Apr. 17	Neurotech's Phase II/III NTIASD2 Clinical Trial for Children with Autism Meets Primary Endpoint	MT
Apr. 17	Neurotech International Completes AU$10 Million Capital Raise	MT

Neurotech International Limited Reports Earnings Results for the Half Year Ended December 31, 2020

February 25, 2021 at 09:02 pm EST

Neurotech International Limited announced earnings results for the half year ended December 31, 2020. For the half year, the company announced sales was AUD 30,754 compared to AUD 36,387 a year ago. Net loss was AUD 3.622 million compared to AUD 763,327 a year ago. Basic loss per share from continuing operations was AUD 0.0101 compared to AUD 0.0056 a year ago.

Latest news about Neurotech International Limited

Neurotech's Phase II/III NTIASD2 Clinical Trial for Children with Autism Meets Primary Endpoint	Apr. 17	MT
Neurotech International Completes AU$10 Million Capital Raise	Apr. 16	MT
Neurotech International Concludes Phase II/III NTIASD2 Trial for Children with Autism	Apr. 09	MT
Neurotech International Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 26	CI
Neurotech Receives Human Research Ethics Committee Approval to Extend Autism Trial	Feb. 12	MT
Neurotech's ASD Drug Trials Exceed 90 Weeks	Feb. 07	MT
Neurotech International Secures Approval to Advance Cerebral Palsy Trial; Shares Rise 6%	Jan. 28	MT
Neurotech International Completes Enrolment for Phase 2/3 Autism Spectrum Trial	Dec. 19	MT
Neurotech International Secures Ethics Approval for Use of Autism Spectrum Medication in Adults	Dec. 04	MT
Neurotech International Secures AU$3 Million R&D Tax Rebate for Fiscal Year 2023	Nov. 14	MT
Neurotech International Completes Enrollment for Rett Syndrome Trial	23-09-26	MT
Neurotech International Completes Treatment for Last Patient in Phase I/II PANDAS/PANS Clinical Trial	23-08-30	MT
Neurotech International Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-30	CI
Neurotech International Secures Ethics Approval for Clinical Trial of Neurological Medication	23-07-10	MT
Neurotech International Secures Ethics Approval to Extend Use of Medication in Pediatric Trial	23-05-30	MT
Neurotech International Completes Patient Recruitment for Neuropsychiatric Disorder Treatment Trial	23-05-03	MT
Neurotech International Plans to Launch Phase Two Rett Syndrome Trial	23-03-20	MT
Neurotech International Limited Announces the Launch of A New Clinical Program in Rett Syndrome, Commencement of A Phase II Clinical Trial Investigating the Use of NTI164 in Female Patients	23-03-19	CI
Neurotech International Says Considerable Improvement in ASD Patients Treated with NTI164; Shares Decline 9%	23-03-16	MT
Neurotech International Limited Announces the Final Clinical Results from Eleven Paediatric Autism Spectrum Disorder Patients, Following Daily Treatment of NTI164 over 52 Week Period	23-03-16	CI
Neurotech International Halts Trade Pending Release of Clinical Trial Data	23-03-15	MT
Neurotech International Limited Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-28	CI
Neurotech International Limited Announces First Patient Treated in Phase I/II PANDAS/PANS Trial	23-02-15	CI
Neurotech International Secures Ethics Approval to Extend Phase 1/2 Autism Trial	23-02-14	MT
Neurotech International Limited Announces Approval for Additional Phase I/II ASD Trial Extension	23-02-13	CI

Chart Neurotech International Limited

Duration

Period

More charts

Company Profile

Neurotech International Limited is an Australia-based clinical-stage biopharmaceutical development company. The Company is focused on the development and commercialization of neurological solutions focused predominately on pediatric neurological disorders. The Company conducts clinical studies to assess the neuro-protective, anti-inflammatory, and neuro-modulatory activities of its NTI/Dolce cannabis strains. It is also commercializing Mente, a home therapy to increase engagement and improve relaxation in autistic children with elevated delta-band brain activity. Its product, Mente Autism, assists with the management of children with autism spectrum disorder (ASD). Its development program NTI164 completed a Phase I/II clinical trial to treat patients with autism spectrum disorder (ASD). Mente Autism is a portable, electroencephalographic (EEG) medical device for home use in the form of a headband that uses closed-loop neurofeedback to helo-relax the minds of children with ASD.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-08-27 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Medical Monitoring Systems

	1st Jan change	Capi.
NEUROTECH INTERNATIONAL LIMITED	+30.43%	53.57M
IRHYTHM TECHNOLOGIES, INC.	+4.59%	3.62B
EKF DIAGNOSTICS HOLDINGS PLC	-12.16%	157M
MEDIANA CO.,LTD	-15.28%	84.57M

Medical Monitoring Systems